Amie A. Lette, Pharm D, Ms
About Amie A. Lette, Pharm D, Ms
Amie A. Lette, Pharm D, Ms, is currently a Postdoctoral Fellow in US Oncology Market Access at Bristol Myers Squibb in the New York City Metropolitan Area. She has a diverse background in pharmacy, regulatory science, and market access, with experience at companies such as CareFirst BlueCross BlueShield, Amgen, Novartis Gene Therapies, and Johns Hopkins Hospital.
Current Role at Bristol Myers Squibb
Amie A. Lette is currently working as a Postdoctoral Fellow in US Oncology Market Access at Bristol Myers Squibb. Based in the New York City Metropolitan Area, she contributes to strategies related to oncology market access, focusing on optimizing patient outcomes through effective market strategies.
Experience at CareFirst BlueCross BlueShield
Amie A. Lette served as a Managed Care Pharmacy Extern at CareFirst BlueCross BlueShield. During her one-month tenure in Washington, DC, in 2023, she gained valuable experience in managed care pharmacy, working on projects that likely contributed to the understanding of pharmacy benefits management and patient care coordination.
Internship at Amgen
In 2022, Amie A. Lette took on the role of a Commercial Insights Intern at Amgen in Thousand Oaks, California. Over the two-month internship, she engaged in gathering and analyzing market data to support commercial strategy and product positioning in the pharmaceutical industry.
Educational Background
Amie A. Lette has a robust academic background. She earned her Doctor of Pharmacy (PharmD) degree from the University of Maryland School of Pharmacy. Additionally, she holds a Master of Science (MS) in Regulatory Science from the University of Maryland, Baltimore (UMB) and a Bachelor's degree in Chemistry from Frostburg State University. Moreover, she completed her Post-Doctoral Fellowship at Rutgers University.
Positions at Johns Hopkins Hospital and Inotiv
Amie A. Lette worked as a Pediatric Intern and Research Assistant at Johns Hopkins Hospital in Baltimore, Maryland, for one year from 2020 to 2021. Additionally, she was involved in Dose Formulations and Analysis for Preclinical Drug Development at Inotiv in Gaithersburg, Maryland, spending two years in this role from 2017 to 2019. These positions provided her with substantial research and clinical experience.